AbCellera Biologics (ABCL) EPS (Weighted Average and Diluted) (2020 - 2023)
Historic EPS (Weighted Average and Diluted) for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$0.17.
- AbCellera Biologics' EPS (Weighted Average and Diluted) fell 7000.0% to -$0.17 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.52, marking a year-over-year decrease of 20400.0%. This contributed to the annual value of -$0.55 for FY2024, which is 784.31% down from last year.
- Latest data reveals that AbCellera Biologics reported EPS (Weighted Average and Diluted) of -$0.17 as of Q4 2023, which was down 7000.0% from -$0.1 recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' EPS (Weighted Average and Diluted) ranged from a high of $0.54 in Q1 2022 and a low of -$0.17 during Q4 2023
- Its 4-year average for EPS (Weighted Average and Diluted) is $0.06, with a median of -$0.02 in 2020.
- Per our database at Business Quant, AbCellera Biologics' EPS (Weighted Average and Diluted) surged by 380000.0% in 2021 and then crashed by 42833.87% in 2023.
- Quarter analysis of 4 years shows AbCellera Biologics' EPS (Weighted Average and Diluted) stood at $0.44 in 2020, then crashed by 56.82% to $0.19 in 2021, then tumbled by 152.63% to -$0.1 in 2022, then crashed by 70.0% to -$0.17 in 2023.
- Its EPS (Weighted Average and Diluted) stands at -$0.17 for Q4 2023, versus -$0.1 for Q3 2023 and -$0.11 for Q2 2023.